欢迎来到《四川大学学报(医学版)》

不同分化程度的口腔鳞状细胞癌组织中蛋白激酶D的表达

陈红利 崔博淼 康颖竹 王利伟 王京楠 冯云 张平 吕蝶 陈娇

陈红利, 崔博淼, 康颖竹, 等. 不同分化程度的口腔鳞状细胞癌组织中蛋白激酶D的表达[J]. 四川大学学报(医学版), 2020, 51(6): 755-759. doi: 10.12182/20201160505
引用本文: 陈红利, 崔博淼, 康颖竹, 等. 不同分化程度的口腔鳞状细胞癌组织中蛋白激酶D的表达[J]. 四川大学学报(医学版), 2020, 51(6): 755-759. doi: 10.12182/20201160505
CHEN Hong-li, CUI Bo-miao, KANG Ying-zhu, et al. Expression Level of Protein Kinase D in Oral Squamous Cell Carcinoma with Diverse Differentiation[J]. JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCE EDITION), 2020, 51(6): 755-759. doi: 10.12182/20201160505
Citation: CHEN Hong-li, CUI Bo-miao, KANG Ying-zhu, et al. Expression Level of Protein Kinase D in Oral Squamous Cell Carcinoma with Diverse Differentiation[J]. JOURNAL OF SICHUAN UNIVERSITY (MEDICAL SCIENCE EDITION), 2020, 51(6): 755-759. doi: 10.12182/20201160505

栏目: 口腔医学进展

不同分化程度的口腔鳞状细胞癌组织中蛋白激酶D的表达

doi: 10.12182/20201160505
基金项目: 国家自然科学基金(No.81802717)资助
详细信息
    通讯作者:

    E-mail:cj123@163.com

Expression Level of Protein Kinase D in Oral Squamous Cell Carcinoma with Diverse Differentiation

More Information
  • 摘要:   目的  探索口腔鳞状细胞癌(oral squamous cell carcinoma, OSCC)组织中蛋白激酶D(protein kinase D, PKD)1、2、3的表达情况及其与口腔鳞癌分化程度的关系。  方法  收集10例正常口腔上皮组织、40例OSCC组织样本,采用免疫组化SP法检测PKD1、PKD2和PKD3的表达,评判阳性细胞比率及对染色强度进行评分,分析不同分化程度的OSCC组织中PKD1、PKD2和PKD3间的差异性,并分析PKD1、PKD2和PKD3免疫组化染色评分与OSCC分化程度的相关性。  结果  PKD1和PKD3在OSCC组织中高表达;不同分化程度的OSCC组织中,PKD1、PKD2及PKD3免疫组化染色评分间差异均有统计学意义(P<0.001);PKD1和PKD2的免疫组化染色评分与OSCC分化程度呈负相关关系(r分别为−0.574和−0.341, P<0.001)。  结论  不同分化程度的OSCC组织中,起主导作用的PKDs可能存在差异;PKD1和PKD2的表达水平与OSCC的分化程度存在相关性,OSCC分化程度越低,PKD1及PKD2的表达越高。
  • 图  1  PKD1、PKD2和PKD3在不同分化程度OSCC组织中的免疫组化染色结果(标尺=100 μm)

    Figure  1.  The immunohistochemical staining of PKD1, PKD2 and PKD3 in diverse differentiation OSCC tissues (scale bar=100 μm)

    表  1  PKD1、PKD2和PKD3在高分化、中分化及低分化OSCC组织中的免疫组化染色评分及其与OSCC分化程度的相关性

    Table  1.   The immumohistochemical (IHC) score of PKD1, PKD2 and PKD3 in well differentiated OSCC, moderately differentiated OSCC and poorly differentiated OSCC, and the correlation between the IHC score of PKDs with the differentiation of OSCC

    Differentiation degreenPKD1PKD2PKD3P
    IHC scorerPIHC scorerPIHC scorerP
    Well differentiated155.67±1.76−0.574<0.0011.11±1.17−0.341<0.0016.89±2.41−0.0730.389<0.001
    Moderately
     differentiated
    15
    8.00±3.69
    1.24±1.75
    7.11±3.55*
    <0.001
    Poorly differentiated1011.30±3.64*3.00±1.947.63±3.32*<0.001
     *P<0.001, vs. well differentiated.
    下载: 导出CSV
  • [1] 桂心伟, 姚小武, 陈仕生, 等. NF-κB在口腔鳞状细胞癌及癌旁组织中的表达意义. 口腔疾病防治,2019,27(6): 360–363.
    [2] TANG D, TAO D, FANG Y, et al. TNF-alpha promotes invasion and metastasis via NF-Kappa B pathway in oral squamous cell carcinoma. Med Sci Monit Basic Res,2017,23: 141–149. doi: 10.12659/MSMBR.903910
    [3] WANG P, LIU J, SONG Y, et al. Screening of immunosuppressive factors for biomarkers of breast cancer malignancy phenotypes and subtype-specific targeted therapy. Peer J,2019,7: e7197[2019-09-21].https://doi.org/10.7717/peerj.7197. doi: 10.7717/peerj.7197
    [4] WANG X, BAI Y, HAN Y, et al. Downregulation of GBAS regulates oral squamous cell carcinoma proliferation and apoptosis via the p53 signaling pathway. Onco Targets Ther,2019,12: 3729–3742. doi: 10.2147/OTT.S207930
    [5] ASHE S, YADAV S. Maintenance of rhodopsin levels in drosophila photoreceptor and phototransduction requires protein kinase D. Fly(Austin),2018,12(3/4): 164–173.
    [6] BORGES S, PEREZ E A, THOMPSON E A, et al. Effective targeting of estrogen receptor-negative breast cancers with the protein kinase D inhibitor CRT006610111306. Mol Cancer Ther,2015,14(6): 1306–1316. doi: 10.1158/1535-7163.MCT-14-0945
    [7] 余宇, 卢婉鹭, 陈娇, 等. 蛋白激酶D1沉默可降低人涎腺腺样囊性癌细胞ACC-2对紫杉醇的敏感度. 肿瘤防治研究,2016,43(6): 448–452. doi: 10.3971/j.issn.1000-8578.2016.06.003
    [8] XU X H, JIN T. The novel functions of the PLC/PKC/PKD signaling axis in G protein-coupled receptor-mediated chemotaxis of neutrophils. J Immunol Res,2015,2015: 817604[2019-12-13]. https://doi.org/10.1155/2015/817604. doi: 10.1155/2015/817604
    [9] WANG Q J. PKD at the crossroads of DAG and PKC signaling. Trends Pharmacol Sci,2006,27(6): 317–323. doi: 10.1016/j.tips.2006.04.003
    [10] BORGES S, DÖPPLER H, PEREZ E A, et al. Pharmacologic reversion of epigenetic silencing of the PRKD1 promoter blocks breast tumor cell invasion and metastasis. Breast Cancer Res,2013,15(2): R66[2019-12-13]. https://doi.org/10.1186/bcr3460. doi: 10.1186/bcr3460
    [11] EISELER T, DÖPPLER H, YAN I K, et al. Protein kinase D1 regulates matrix metalloproteinase expression and inhibits breast cancer cell invasion. Breast Cancer Res,2009,11(1): R13[2019-12-13]. https://doi.org/10.1186/bcr2232. doi: 10.1186/bcr2232
    [12] DURAND N, BORGES S, STORZ P. Functional and therapeutic significance of protein kinase D enzymes in invasive breast cancer. Cell Mol Life Sci,2015,72(22): 4369–4382. doi: 10.1007/s00018-015-2011-2
    [13] SOLOMON B, YOUNG R J, RISCHIN D. Head and neck squamous cell carcinoma: genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol,2018,52: 228–240. doi: 10.1016/j.semcancer.2018.01.008
    [14] CHI A C, DAY T A, NEVILLE B W. Oral cavity and oropharyngeal squamous cell carcinoma—an update. CA Cancer J Clin,2015,65(5): 401–421. doi: 10.3322/caac.21293
    [15] RYKX A, DEKIMPE L, MIKHALAP S, et al. Protein kinase D: a family affair. FEBS Lett,2003,546(1): 81–86. doi: 10.1016/S0014-5793(03)00487-3
    [16] ISHIKAWA E, KOSAKO H, YASUDA T, et al. Protein kinase D regulates positive selection of CD4+ thymocytes through phosphorylation of SHP-1. Nat Commun, 2016, 7: 12756[2019-12-13]. https://doi.org/10.1038/ncomms12756.
    [17] OLAYIOYE M A, BARISIC S, HAUSSER A. Multi-level control of actin dynamics by protein kinase D. Cell Signal,2013,25(9): 1739–1747. doi: 10.1016/j.cellsig.2013.04.010
    [18] DöPPLER H, BASTEA L I, BORGES S, et al. Protein kinase D isoforms differentially modulate cofilin-driven directed cell migration. PLoS One, 2014, 9(5): e98090[2019-09-21]. https://doi.org/10.1371/journal.pone.0098090.
    [19] STARUSCHENKO A. To cleave or not to cleave: role of ADAM17 in cell proliferation in PKD. Am J Physiol Renal,2014,307(6): F658–F659. doi: 10.1152/ajprenal.00341.2014
    [20] EISLER S A, CURADO F, LINK G, et al. A Rho signaling network links microtubules to PKD controlled carrier transport to focal adhesions. eLife, 2018, 7: e35907[2019-09-21]. https://doi.org/10.7554/eLife.35907.001.
    [21] DURAND N, BORGES S, STORZ P. Protein kinase D enzymes as regulators of EMT and cancer cell invasion. J Clin Med,2016,5(2): 20[2019-09-21]. https://doi.org/10.3390/jcm5020020. doi: 10.3390/jcm5020020
    [22] XU W, QIAN J, ZENG F, et al. Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment. J Exp Clin Canc Res,2019,38(1): 114[2019-09-21]. https://doi.org/10.1186/s13046-019-1118-y. doi: 10.1186/s13046-019-1118-y
    [23] SUHA S, REY O, ROZENGURT E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res,2002,62(6): 1632–1640.
    [24] SHABELNIK M Y, KOVALEVSKA L M, YURCHENKO M Y, et al. Differential expression of PKD1 and PKD2 in gastric cancer and analysis of PKD1 and PKD2 function in the model system. Exp Oncol,2011,33(4): 206–211.
    [25] KIM M, JANG H R, KIM J H, et al. Epigenetic inactivation of protein kinase D1 in gastric cancer and its role in gastric cancer cell migration and invasion. Carcinogenesis,2007,29(3): 629–637. doi: 10.1093/carcin/bgm291
    [26] CHEN J, DENG F, SINGH S V, et al. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKC/PKD3 pathway downstream of Akt and ERK 1/2. Cancer Res,2008,68(10): 3844–3853. doi: 10.1158/0008-5472.CAN-07-5156
    [27] TANDON M, JOHNSON J, LI Z, et al. New pyrazolopyrimidine inhibitors of protein kinase D as potent anticancer agents for prostate cancer cells. PLoS One, 2013, 8(9): e75601[2019-09-21]. https://doi.org/10.1371/journal.pone.0075601.
    [28] LIU Y, WANG Y, YU S, et al. The role and mechanism of CRT0066101 as an effective drug for treatment of triple-negative breast cancer. Cell Physiol Biochem,2019,52(3): 382–396. doi: 10.33594/000000027
    [29] LIU Y, LI J, MA Z, et al. Oncogenic functions of protein kinase D2 and D3 in regulating multiple cancer-related pathways in breast cancer. Cancer Med,2019,8(2): 729–741. doi: 10.1002/cam4.1938
    [30] ZOU Z, ZENG F, XU W, et al. PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-kB- and HDAC1-mediated expression and activation of uPA. J Cell Sci,2012,125(20): 4800–4811. doi: 10.1242/jcs.106542
    [31] HUCK B, DUSS S, HAUSSER A, et al. Elevated protein kinase D3(PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J Biol Chem,2014,289(6): 3138–3147. doi: 10.1074/jbc.M113.502633
    [32] BASTEA L I, DÖPPLER H, BALOGUN B, et al. Protein kinase D1 maintains the epithelial phenotype by inducing a DNA-bound, inactive SNAI1 transcriptional repressor complex. PLoS One,2012,7(1): e30459[2019-09-21]. https://doi.org/10.1371/journal.pone.0030459. doi: 10.1371/journal.pone.0030459
    [33] RYVKIN V, RASHEL M, GADDAPARA T, et al. Opposing growth regulatory roles of protein kinase D isoforms in human keratinocytes. J Biol Chem,2015,290(17): 11199–11208. doi: 10.1074/jbc.M115.643742
    [34] MARKLUND U, LIGHTFOOT K, CANTRELL D. Intracellular location and cell context-dependent function of protein kinase D. Immunity,2003,19(4): 491–501. doi: 10.1016/S1074-7613(03)00260-7
  • 加载中
图(1) / 表(1)
计量
  • 文章访问数:  1708
  • HTML全文浏览量:  549
  • PDF下载量:  22
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-11-14
  • 修回日期:  2020-05-22
  • 刊出日期:  2020-11-20

目录

    /

    返回文章
    返回